Quantcast

Latest Microbiome Stories

2014-09-19 12:25:43

DUBLIN, Sept. 19, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 For the purposes of this report, the human microbiome market is segmented by application, disease, product, and geography. The human microbiome market is expected to be valued as $294 million in 2019 and...

2014-09-18 23:07:02

The human microbiome market is divided into three major segments, namely, application, disease, and product. http://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html (PRWEB) September 18, 2014 The "Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) –Global Forecast to 2023",...

2014-09-10 16:25:54

DALLAS, September 10, 2014 /PRNewswire/ -- According to the new market research report "Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Other Supplements, Device, Drug) - Global Forecast to 2023", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current...

2014-09-09 08:31:20

Former Pfizer Executive to Lead R&D at Second Genome SOUTH SAN FRANCISCO, Calif., Sept. 9, 2014 /PRNewswire/ -- Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company's Chief Scientific Officer. In this new position, Dr. Dabbagh will be responsible for the company's drug pipeline, fueled by Second Genome's novel discovery platform for identifying and...

2014-09-08 16:25:18

Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced final data for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic. SER-109, a mixture of bacterial spores, is designed for the treatment of recurrent...

2014-08-28 12:29:24

CAMBRIDGE, Mass., Aug. 28, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, announced today that Dr. David Cook, Seres' Executive Vice President of R&D and Chief Scientific Officer, will be presenting at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentation will highlight the scientific and medical implications of SER-109, a novel mixture...

cravings and bacteria
2014-08-18 05:00:59

April Flowers for redOrbit.com - Your Universe Online Our bodies play host to millions of bacteria. In fact, they outnumber our own cells by about 100-fold. And yet, we hold the notion that we are in charge of our own lives, not the bacteria that has just hitched a ride. A new study, published in BioEssays, tells a different story. The findings reveal that the bacteria within our bodies may very well be affecting our cravings and our moods to ensure that we eat what they want. The...

diet gut flora
2014-07-30 05:21:02

April Flowers for redOrbit.com - Your Universe Online It has been evident for a while that men and women react to diet differently. Men lose weight easier than women, men need more calories than women because of muscle mass, and there are even differences in eating styles. Now, a new study led by The University of Texas at Austin reveals that even our gut microbes react differently to our diet, even if that diet is exactly the same. The findings, published in Nature Communication,...

2014-07-29 16:26:15

Researchers Look to Target Gut Microbiome for Treatment and Prevention of Crohn's Disease and Ulcerative Colitis NEW YORK, July 29, 2014 /PRNewswire/ -- Early findings from a major research initiative of the Crohn's & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the...

2014-07-07 12:28:38

Company's Breakthrough Innovation to Enable First Therapeutics for Microbiome-based Diseases CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical composition patent application that covers its lead product candidate, SER-109, which is currently...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.